Democrats and Republicans on the House Energy and Commerce Committee appear no closer to resolving differences around prescription drug shortages after a legislative hearing in the Health Subcommittee on Thursday.
The debate is entangled in a stalled reauthorization of a pandemic and emergency preparedness law that expires Sept. 30.
The U.S. is facing an ongoing shortage of critical medications for conditions like cancer, which recently prompted the Food and Drug Administration to loosen import restrictions for cisplatin, a generic chemotherapy drug. Fourteen other cancer drugs remain in short supply, the White House Office of Science and Technology Policy said Sept. 12.
